Identification of four novel potentially Parkinson's disease associated LRRK2 variations among Iranian patients

Neuroscience Letters

Volumn 467, Issue 2, 2009, Pages 53-57

  Shojaee, Seyedmehdi ^a,b   Fazlali, Zeinab ^a   Ghazavi, Farzaneh ^a   Banihosseini, Setareh Sadat ^c   Kazemi, Mohammad Hossein ^c   Parsa, Khosro ^d   Sadeghi, Homa ^d   Sina, Farzad ^e   Shahidi, Gholam Ali ^e   Ronaghi, Mostafa ^f   Elahi, Elahe ^a,g  

^a UNIVERSITY OF TEHRAN   (Iran)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Statistics and Computer Science   (Iran)

Author keywords

IVS49+178A>G; LRRK2; p.D2175H; p.Q1823K; p.R1725Q; Parkinson's disease

Indexed keywords

ADENINE; ARGININE; ASPARTIC ACID; GLUTAMINE; GUANINE; HISTIDINE; ISOLEUCINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; LYSINE; SERINE; VALINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EXON; FAMILY STUDY; HETEROZYGOSITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONSET AGE; PARKINSON DISEASE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN VARIANT; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; AGE OF ONSET; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 70350564899     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.09.058     Document Type: Article

References (32)

1. Barrett J., Fry B., Maller J., and Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
2. Berg D., Schweitzer K.J., Leitner P., Zimprich A., Lichtner P., Belcredi P., Brussel T., Schulte C., Maass S., Nagele T., Wszolek Z.K., and Gasser T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128 (2005) 3000-3011
3. Bras J.M., Guerreiro R.J., Ribeiro M.H., Januario C., Morgadinho A., Oliveira C.R., Cunha L., Hardy J., and Singleton A. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov. Disord. 20 (2005) 1653-1655
4. Chitsazian F., Tusi B., Elahi E., Saroei H., Sanati M., Yazdani S., Pakravan M., Nilforooshan N., Eslami Y., Mehrjerdi M., Zareei R., Jabbarvand M., Abdolahi A., Lasheyee A., Etemadi A., Bayat B., Sadeghi M., Banoei M., Ghafarzadeh B., Rohani M., Rismanchian A., Thorstenson Y., and Sarfarazi M. CYP1B1 mutation profile of Iranian primary congenital glaucoma patients and associated haplotypes. J. Mol. Diagn. 9 (2007) 382-393
5. Elahi E., Khodadad A., Kupershmidt I., Ghasemi F., Alinasab B., Naghizadeh R., Eason R., Amini M., Esmaili M., Dooki M.E., Sanati M., Davis R., Ronaghi M., and Thorstenson Y. A haplotype framework for cystic fibrosis mutations in Iran. J. Mol. Diagn. 8 (2006) 119-127
6. Elbaz N.A. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease. Lancet Neurol. 7 (2008) 562-564
7. Farrer M.J., Stone J.T., Lin C.-H., Dachsel J.C., Hulihan M.M., Haugarvoll K., Ross O.A., and Wu R.-M. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13 (2007) 89-92
8. Fonzo A.D., Wu-Chou Y.-H., Lu C.-S., Doeselaar M.v., Simons E.J., Rohé C.F., Chang H.-C., Chen R.-S., Weng Y.-H., Vanacore N., Breedveld G.J., Oostra B.A., and Bonifati V. A common missense variant in the LRRK2gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7 (2006) 133-138
9. Gaig C., Ezquerra M., Marti M.J., Munoz E., Valldeoriola F., and Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease. Arch. Neurol. 63 (2006) 377-382
10. Haugarvoll K., Rademakers R., Kachergus J.M., Nuytemans K., Ross O.A., Gibson J.M., Tan E.-K., Gaig C., Tolosa E., Goldwurm S., Guidi M., Riboldazzi G., Brown L., Walter U., Benecke R., Berg D., Gasser T., Theuns J., Pals P., Cras P., Deyn P.P.D., Engelborghs S., Pickut B., Uitti R.J., Foroud T., Nichols W.C., Hagenah J., Klein C., Samii A., Zabetian C.P., Bonifati V., Broeckhoven C.V., Farrer M.J., and Wszolek Z.K. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70 (2008) 1456-1460
11. Hedrich K., Djarmati A., Schäfer N., Hering R., Wellenbrock C., Weiss P.H., Hilker R., Vieregge P., Heutink L.J.O.P., Bonifati V., Schwinger E., Lang A.E., Noth J., Bressman S.B., Pramstaller P.P., Riess O., and Klein C. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62 (2004) 389-394
12. Hedrich K., Winkler S., Hagenah J., Kabakci K., Kasten M., Schwinger E., Volkmann J., Pramstaller P.P., Kostic V., Vieregge P., and Klein C. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov. Disord. 21 (2006) 1506-1510
13. Hernandez D.G., Paisán-Ruíz C., McInerney-Leo A., Jain S., Meyer-Lindenberg A., Evans E.W., Berman K.F., Johnson J., Auburger G., Schäffer A.A., Lopez G.J., Nussbaum R.L., and Singleton A.B. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann. Neurol. 57 (2005) 453-456
14. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H., Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K., Farrer M.J., and Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76 (2005) 672-680
15. Latourelle J., Sun M., Lew M., Suchowersky O., Klein C., Golbe L., Mark M., Growdon J., Wooten G., Watts R., Guttman M., Perlmutter B.R.J., Ahmed A., Shill H., Singer C., Goldwurm S., Pezzoli G., Zini M., Hendricks M.S.-H.A., Williamson S., Nagle M., Wilk J., Massood T., Huskey K., Laramie J., DeStefano A., Baker K., Itin I., Litvan I., Nicholson G., Corbett A., Nance M., Drasby E., Isaacson S., Burn D., Chinnery P., Pramstaller P., Al-hinti J., Moller A., Ostergaard K., Sherman S., Snow R.R.B., Slevin J., Cambi F., Gusella J., and Myers R. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 6 (2008) 32
16. Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F.o., Tazir M., Leutenegger A.-L., Guimaraes J., Bonnet A.-M., Agid Y., Dürr A., and Brice A. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58 (2005) 784-787
17. Li C., Ting Z., Qin X., Ying W., Li B., Qiang L.G., Fang M.J., Jing Z., Qing D.J., and Di C.S. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. Mov. Disord. 22 (2007) 2439-2443
18. Lu C.-S., Simons E.J., Wu-Chou Y.-H., Fonzo A.D., Chang H.-C., Chen R.-S., Weng Y.-H., Rohe C.F., Breedveld G.J., Hattori N., ThomasGasser, Oostra B.A., and Bonifati V. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat. Disord. 11 (2005) 521-522
19. Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C., Blazquez M., Guisasola L.M., Salvador C., Ribacoba R., Martinez C., Farrer M., and Alvarez V. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci. Lett. 382 (2005) 309-311
20. Mizuno Y., Hattori N., Mori H., Suzuki T., and Tanaka K. Parkin and Parkinson's disease. Curr. Opin. Neurol. 14 4 (2001) 477-482
21. Nuytemans K., Rademakers R., Theuns J., Pals P., Engelborghs S., Pickut B., Pooter T.d., Peeters K., Mattheijssens M., Broeck M.V.d., Cras P., Deyn P.P.D., and Broeckhoven C.v. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur. J. Hum. Genet. 16 (2008) 1-9
22. Ozelius L.J., Geetha Senthil P.D., Saunders-Pullma R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., Lipton R.B., Soto-Valencia J., Risch N., and Bressman S.B. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354 (2006) 424-425
23. Paisan-Rui{dotless}z C., Jain S., Evans E.W., Gilks W.P., Simon J., Brug M.v.d., Munain A.L.d., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., Silva R.d., Lees A., Marti{dotless}-Masso J., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that Cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
24. Paisan-Rui{dotless}z C., Nath P., Washecka N., Gibbs J.R., and Singleton A.B. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum. Mutat. 29 (2008) 485-490
25. Rijk M.d., Breteler M., Graveland G., Ott A., Grobbee D., Meché F.v.d., and Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 45 (1995) 2143-2146
26. Ross O.A., Wu Y.-R., Lee M.-C., Funayama M., Chen M.-L., Soto A.I., Mata I.F., Lee-Chen G.-J., Chen C.M., Tang M., Zhao Y., Hattori N., Farrer M.J., Tan E.-K., and Wu R.-M. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64 (2008) 88-92
27. Saunders-Pullman R., Lipton R.B., Senthil G., Katz M., Costan-Toth C., Derby C., Bressman S., Verghese J., and Ozelius L.J. Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci. Lett. 402 (2006) 92-96
28. Shojaee S., Sina F., Farboodi N., Fazlali Z., Ghazavi F., Ghorashi S.A., Parsa K., Sadeghi H., Shahidi G.-A., Ronaghi M., and Elahi E. A clinic-based screening of mutations in exons 31, 34, 35, 41 and 48 of LRRK2 in Iranian Parkinson's disease patients. Mov. Disord. 24 7 (2009) 1023-1027
29. Valente E., Brancati F., Ferraris A., Graham E., Davis M., Breteler M., Gasser T., Bonifati V., Bentivoglio A., Michele G.D., Dürr A., Ortelli P., Wassilowsky D., Harhangi B., Rawal N., Caputo V., Filla A., Meco G., Oostra B., Brice A., Albanese A., Dallapiccola B., and Wood N. E.C.o.G.S.i.P.s. disease, PARK6-linked parkinsonism occurs in several European families. Ann. Neurol. 51 1 (2002) 14-18
30. Wood-Kaczmar A., Gandhi S., and Wood N. Understanding the molecular causes of Parkinson's disease. Trends Mol. Med. 12 (2006) 521-528
31. Zabetian C.P., Samii A., Mosley A.D., Roberts J.W., Leis B.C., Yearout D., Raskind W.H., and Griffith M.A. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005) 741-744
32. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607